These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17406366)

  • 1. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract.
    Formica V; Wotherspoon A; Cunningham D; Norman AR; Sirohi B; Oates J; Chong G
    Br J Cancer; 2007 Apr; 96(8):1178-82. PubMed ID: 17406366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
    Hijioka S; Hosoda W; Mizuno N; Hara K; Imaoka H; Bhatia V; Mekky MA; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutumi H; Fujiyoshi T; Sato T; Hieda N; Yoshida T; Okuno N; Shimizu Y; Yatabe Y; Niwa Y; Yamao K
    J Gastroenterol; 2015 May; 50(5):564-72. PubMed ID: 25142799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back.
    La Rosa S; Sessa F
    Endocr Pathol; 2014 Jun; 25(2):193-8. PubMed ID: 24715269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
    Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
    Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
    Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
    Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
    Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
    Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
    Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
    Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Clinical Analysis of Gastroenteropancreatic Neuroendocrine Carcinomas with Liver Metastasis and Primary Hepatic Neuroendocrine Carcinomas.
    Qiu MJ; Chen YB; Bi NR; Yang SL; He XX; Xiong ZF
    Dis Markers; 2018; 2018():9191639. PubMed ID: 30416612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of diagnosing colorectal neuroendocrine carcinoma using the World Health Organization 2010 classification.
    Lee JL; Yu CS; Kim M; Hong SM; Lim SB; Kim JC
    Surgery; 2014 Apr; 155(4):650-8. PubMed ID: 24468036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivals of patients with surgically treated and High-grade pancreatic neuroendocrine carcinomas: A comparative study between two American Joint Committee on Cancer 8th tumor-node-metastasis staging systems.
    Yang M; Zhang Y; Zeng L; Ke NW; Tan CL; Tian BL; Xiang B; Liu XB
    Eur J Surg Oncol; 2019 Jun; 45(6):1054-1060. PubMed ID: 30661921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual.
    Deng BY; Yang M; Wen JY; Hou SZ; Chen Y; Tian BL; Liu XB; Zhang Y
    Medicine (Baltimore); 2020 Jan; 99(3):e18736. PubMed ID: 32011453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
    Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
    Oncologist; 2019 Jul; 24(7):911-920. PubMed ID: 30482824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms?
    Thornblade LW; Warner SG; Melstrom L; Ituarte PHG; Chang S; Li D; Fong Y; Singh G
    Surgery; 2021 Jun; 169(6):1417-1423. PubMed ID: 33637345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
    Shia J; Tang LH; Weiser MR; Brenner B; Adsay NV; Stelow EB; Saltz LB; Qin J; Landmann R; Leonard GD; Dhall D; Temple L; Guillem JG; Paty PB; Kelsen D; Wong WD; Klimstra DS
    Am J Surg Pathol; 2008 May; 32(5):719-31. PubMed ID: 18360283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
    Durante C; Boukheris H; Dromain C; Duvillard P; Leboulleux S; Elias D; de Baere T; Malka D; Lumbroso J; Guigay J; Schlumberger M; Ducreux M; Baudin E
    Endocr Relat Cancer; 2009 Jun; 16(2):585-97. PubMed ID: 19240182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.